Truqap (Capivasertib) for Breast Cancer

Overview
Truqap is a prescription drug approved by the U.S. Food and Drug Administration (FDA) in combination with fulvestrant to treat some cases of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that is locally advanced or metastatic. Truqap may be considered in adults when breast cancer cells have tested positive for one or more PIK3CA/AKT1/PTEN genetic mutations. Truqap may be recommended in situations where breast cancer has progressed after at least one endocrine-based regimen (hormone therapy) in cases of metastatic (stage 4) breast cancer, or if breast cancer has recurred at or within 12 months of completing adjuvant (initial) therapy. Truqap is also referred to by its drug name, capivasertib.

Truqap is used as targeted therapy for breast cancer. Truqap is a member of a class of drugs called kinase inhibitors. Truqap is believed to work by inhibiting growth in cancer cells.

How do I take it?
Prescribing information states that Truqap is taken orally twice daily.

Truqap comes in tablet form.

Side effects
The FDA-approved label for Truqap lists common side effects including diarrhea, skin reactions, nausea, fatigue, vomiting, and stomach inflammation.

Rare but serious side effects listed for Truqap include high blood glucose (blood sugar), severe diarrhea, and severe skin reactions. Truqap may cause fetal harm if taken during pregnancy.

For more details about this treatment, visit:

Truqap — AstraZeneca
https://www.truqap.com/